Identification of an amyloidogenic region on keratoepithelin via synthetic peptides  by Yuan, Ching et al.
FEBS Letters 581 (2007) 241–247Identiﬁcation of an amyloidogenic region on keratoepithelin via
synthetic peptides
Ching Yuan, Heather L. Berscheit, Andrew J.W. Huang*
Department of Ophthalmology, University of Minnesota, Minneapolis, MN 55455, USA
Received 28 August 2006; revised 5 December 2006; accepted 7 December 2006
Available online 18 December 2006
Edited by Judit Ova´diAbstract Mutations of keratoepithelin (KE) gene in human
chromosome 5q31 have been linked with corneal epithelial or
stromal dystrophies characterized by the abnormal deposits of
amyloid ﬁbrils and/or non-amyloid aggregations in corneal tis-
sue. We report herein that synthetic peptide containing amino
acid (a.a.) residues of 515–532 of native KE protein can readily
form b-sheet-containing amyloid ﬁbrils in vitro. Amyloid ﬁbrils
formed in various conditions from short synthetic peptides (con-
taining a.a. 515–532 and 515–525, respectively) were character-
ized by thioﬂavin T (ThT) ﬂuorescence assay, Congo red
staining, electron microscopy (EM) and circular dichroism
(CD). Triple-N-methylation of the synthetic peptides prevented
the b-sheet polymerization and related amyloid ﬁbril formation.
Comparison study with ThT ﬂuorescence further demonstrated
that synthetic peptides containing corneal dystrophy-related
mutations within this region formed amyloid ﬁbrils to various ex-
tents. Our results suggest that each individual dystrophy-related
mutation by itself does not necessarily potentiate amyloid ﬁbril
formation of KE. Roles of these intrinsically amyloidogenic foci
in abnormal KE aggregations and amyloid deposits of stromal
corneal dystrophies await further investigation.
 2006 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Corneal stromal dystrophies are a diverse group of heredi-
tary disorders associated with abnormal protein deposits in
corneal tissue. Mutations of keratoepithelin (KE), an extracel-
lular matrix protein that was ﬁrst identiﬁed as a transforming
growth factor beta 1 (TGFb-1)-induced protein [1,2], have
been linked to at least 13 clinically and histopathologically dis-
tinct autosomal dominant corneal dystrophies [3–5]. KE con-
sists of 683 amino acids, containing an amino-termial
secretory signal peptide sequence, four ‘‘Fas-like’’ domains
(140 amino acids for each domain) homologous to Droso-
philia fasciclin-1 (Fas-1), and an arginine–glycine–aspartateAbbreviations: KE, keratoepithelin; CD, circular dichroism; TGFb-1,
transforming growth factor beta 1; ThT, thioﬂavin T
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interact with various extracellular matrix proteins [6–9] and
promote cell attachment, migration, proliferation and diﬀeren-
tiation, likely via the interaction with integrins [8,9]. Abnormal
protein deposits in the forms of amyloid ﬁbrils and/or non-
amyloid amorphous aggregations have been found in these
KE-related corneal dystrophies. Although molecular genetics
have unequivocally established the role of KE gene mutations
in human chromosome 5q31 for these corneal dystrophies, the
pathogenic mechanisms responsible for abnormal protein
aggregations remains inconclusive.
Preliminary proteomic studies have suggested that the
abnormal aggregations phenotypic for corneal dystrophies
may be caused by the aberrant turnover and degradation of
mutant KE proteins. When compared with normal corneas,
KE proteins extracted from dystrophic corneas with various
mutations (R124C, R124H and R124L) were noted for the dis-
tinct degradation patterns [10]. In addition, accumulation of a
C-terminal KE fragment was found in the dystrophic corneas
with a F540S mutation [11]. Since cornea remains the only tis-
sue aﬀected by KE mutations [12], other innate characteristics
besides the protein catabolism/degradation are also likely to
contribute to the cornea-speciﬁc abnormal aggregation of mu-
tant KE proteins, as suggested by other authors previously
[13–15].
Amyloidogenesis could also be instigated by intrinsic do-
mains that are either highly amyloidogenic by nature or prone
to interconvert toward b-sheet polymerization upon mutations,
protein unfolding, proteolysis or under other conducive condi-
tions. Using a synthetic peptide and in vitro dialysis approach,
it was shown that peptides with mutations of the R124 (R124C,
R124H, R124S and R124H) displayed enhanced amyloid ﬁbril
formation compared to WT peptide which correlated well with
the clinical ﬁndings in corneal dystrophy patients [16]. How-
ever, discrepancy does exist between the clinical observations
and experimental results. When expressed in transfected
corneal epithelial cells and CHO cells, WT and mutant KE
proteins all displayed similar degradation patterns by immuno-
precipitation and Western blots [17,18]. While KE mutations
are conﬁrmed in most (but not all) of the dystrophic corneas,
both wild-type (WT) and mutant recombinant proteins can
form the phenotypic amyloid ﬁbrils in vitro [17], indicating that
KE proteins are prone to aggregate. This notion is further
supported by the recent report of WT KE aggregations in
non-dystrophic corneas with secondary amyloidosis [15]. It
was also later determined that a shorter peptide with the native
sequence missing R124 residue actually had a much higher
capability to form amyloid ﬁbrils in vitro [13].ation of European Biochemical Societies.
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tains a majority of keratoepithelin mutations (such as muta-
tions of L518, L527 and R555) linked with various corneal
dystrophies [4], the amyloidogenicity of this domain has not
yet been reported. In this study, we investigated amyloid ﬁbril
formation of synthetic peptides containing mutation loci of
KE-related corneal dystrophies located in the 4th Fas-1
domain and have found a previously unreported amyloido-
genic region that can potentially contribute to the abnormal
aggregations of KE. We further demonstrated that the
amyloid ﬁbril formation of this region could be prevented by
N-methylation of the synthetic peptides. The implications of
our ﬁndings in KE-related corneal dystrophies were also dis-
cussed.2. Materials and methods
2.1. Peptide synthesis
All peptides used in this study were custom-synthesized by the Mic-
rochemical facilities at the University of Minnesota using standard
solid phase Fmoc amino acid chemistry and Fmoc-Met Wang resin.
The crude products were further puriﬁed by reverse phase high pres-
sure liquid chromatography with ﬁnal purity greater than 95% and
the sequences were conﬁrmed by fast atom bombardment mass
spectrometry (FAB-MS) and/or matrix-assisted laser desorption mass
spectrometry (MALDI-MS).
2.2. Peptide solutions for amyloid ﬁbril formation
Stock solutions of synthetic peptides were prepared by dissolving
each peptide in DMSO to a concentration of 5 mM. Unless mentioned
otherwise, the stock solutions were further diluted into aqueous solu-
tions and incubated at 37 C for 24 h for amyloid ﬁbril formation
experiments. For the pH-dependent amyloid ﬁbril formation, KE18-
WT (Fig. 1a) was diluted with solutions ranging from pH 4 to 11, con-
taining 150 mM NaCl and 50 mM of sodium citrate, MES, MOPS,
Tris, CHES and CAPS. For the ionic strength-dependent amyloid
ﬁbril formation, KE18-WT was diluted with 10 mM Tris, pH 7.0, buf-
fers with various concentrations of NaCl (0, 50, 150, 250, 500, 1000,
2000 and 4000 mM). Due to the diﬀerence in critical concentrations
for each peptide to form amyloid ﬁbrils in vitro, a higher concentration
of 0.4 mM peptide was chosen based on a previous report [13] to com-
pare WT with mutant peptides.2.3. Thioﬂavin T (ThT) ﬂuorescence
ThT ﬂuorescence assays were conducted according to previous
report [13,16,19]. 50 lL samples from in vitro ﬁbril formation experi-
ments was mixed with 450 lL of 100 lM ThT in 50 mM glycine–
NaOH, pH 8.5, and measured immediately. Scanned ﬂuorescence
spectra and changes in ThT emission were obtained either with a
FluoroMax-II spectroﬂuorometer (Jobin Yvon-SPEX, Edison, NJ,
USA) using an excitation wavelength at 450 nm scanning from 460
to 600 nm in a 0.3 cm cuvette at 25 C, or with a fmax-II ﬂuorescence
plate reader (Molecular Devices, Sunnyvale, CA, USA) using a
444 nm/485 nm ﬁlter set (ex/em) in 96-well plates. For ionic strength-
and pH-dependent amyloid ﬁbril formation, the formed amyloid ﬁbrils
were ﬁrst pelleted by a TL-100 ultracentrifuge (Beckmen Coulter, Ful-
lerton, CA, USA) at 25000 rpm (38500 · g) and then re-suspended in
500 lL ThT solution, as the ﬂuorescence emission of ThT can be
aﬀected by experimental conditions related to pH or ionic strength.
The formed ﬁbrils from KE18-WT and mutant peptides in the compar-
ison study were also centrifuged and then resuspended in ThT solution
as described above.
2.4. TEM and Congo red staining
Negative-stain electron microscopy was used to study the density
and morphology of the ﬁbrils formed under various conditions. Pep-
tide samples (5 ll) were applied onto carbon-coated copper grids
and stained with 2% phosphotungstic acid at room temperature for
two minutes. Excess solution was blotted away with ﬁlter paper andair-dried. The peptide aggregates were examined with a JEOL 1200
transmission electron microscope (TEM) at the Characterization
Facility at the University of Minnesota with an accelerating voltage
of 80 keV to avoid sample damage caused by high-energy electron
beam.
A 10 ll aliquot of samples containing formed ﬁbrils was applied to
gelatin-coated glass slides and allowed to air-dry. The slides were then
stained with Congo red (1 mM) in 1· TBS, rinsed once in water to
remove excess stain and observed with a Zeiss Axiovert 200 light
microscope for birefringence under polarized light.
2.5. Circular dichroism (CD)
The far-UV CD spectra were measured with a Jasco J-710 spectro-
polarimeter (Japan Spectroscopic Co., Tokyo, Japan) to investigate
the interconversion of the secondary structures of synthetic peptides.
To avoid the interference from DMSO, peptide stocks were made in
150 mM NaCl instead and then adjusted to the appropriate pH. Each
peptide spectrum was measured using the average of 10 scans with
blank-subtraction and plotting by Kaleidagraph software (Synergy
Software, Reading, PA, USA).3. Results
3.1. The amyloid ﬁbril formation of KE18-WT peptide
In our in vitro ﬁbril formation experiments, synthetic pep-
tide KE18-WT (Fig. 1a) readily formed amyloid ﬁbrils when
incubated at 37 C in 1· TBS (150 mM NaCl, 10 mM Tris–
HCl, pH 7.0). When compared with ThT only or the control
peptide with a scrambled sequence (‘‘KE18-Scrambled’’),
KE18-WT displayed a signiﬁcantly higher ThT intensity
(Fig. 1b). As measured by the ThT ﬂuorescence intensity,
ﬁbril formation increased from 125 lM of KE18-WT to
0.4 mM in a concentration-dependent manner. No ﬁbrils were
found at concentrations below 50 lM (data not shown). The
aggregations of KE18-WT peptide were shown to be of amy-
loidogenic nature as demonstrated by the Congo red staining
with apple-greenish birefringence when observed under polar-
ized light microscope (Fig. 1c). By electron microscopy,
KE18-WT peptides formed extensive ﬁbrils of several hun-
dreds nm in length with diameters ranging from 5 to 10 nm
(Fig. 1d). Spheres (non-ﬁbril aggregates) of various sizes
(15–45 nm in diameter) were also observed along with those
ﬁbrils. When KE18-WT peptides (125 lM) were incubated
for 24 h in conditions favorable for ﬁbrils formation (such
as pH 7.0) or conditions unfavorable for ﬁbril formation
(pH 9.0, Fig. 2b), two ﬁndings were noted by the far-UV
CD spectroscopy (Fig. 1e): (1) a large negative peak around
200 nm in pH 9.0 shifted toward the longer wavelength and
decreased in amplitude in pH 7.0; (2) an increase of the neg-
ative ellipticity around 220 nm was also noted from pH 9.0 to
pH 7.0. The CD spectrum of KE18-WT in pH 7.0 before incu-
bation (0 h) is similar to that of pH 9.0 after 24 h incubation.
These ﬁndings indicated clear transition from random coils in
pH 9.0 to orderly secondary structures such as b-sheets in pH
7.0.
3.2. Characterization of the amyloidogenesis of KE18-WT
The kinetics of amyloid ﬁbril formation and the eﬀects of
ionic strength and pH on the ﬁbril formation of KE18-WT
were further characterized in vitro. Fluorescence intensities of
ThT at 485 nm were measured for amyloid ﬁbrils formed by
KE18-WT (125 lM) under various conditions. The amyloid
ﬁbril formation progressed relatively fast initially and reached
plateau at 24 h under our testing condition (Fig. 2a). No fur-
Fig. 1. Amyloid ﬁbril formation of the synthetic KE18-WT peptide. (a) Sequences of the KE18-WT and the control peptide with scrambled
sequence. (b) ThT ﬂuorescence spectra of KE18-WT at 0.5 mM (tracing 1), 125 lM (tracing 2), scrambled control peptide (125 lM, tracing 3) and
ThT only (tracing 4). After incubation at 37 C for 24 h in 10 mM Tris–HCl, pH 7.0/150 mMNaCl, samples were mixed with 100 lM of ThT (50 mM
glycine–NaOH, pH 8.5) and their ﬂuorescence intensities were scanned from 460 to 600 nm. The excitation wavelength was 450 nm. (c) Congo red
staining of the amyloid ﬁbrils of KE18-WT under a polarized light microscope (100·, scale bar = 100 lm). (d) Electron micrograph of the negatively
stained amyloid ﬁbrils of KE18-WT. (100000·, scale bar = 100 nm). (e) Far-UV CD spectra of KE18-WT when incubated in a favorable condition
(pH 7) for 0 or 24 h or an unfavorable condition (pH 9.0) for 24 h.
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incubation period. No signiﬁcant ﬁbril formation was noted in
the basic pH conditions (pH 8–11). The optimal pH for ﬁbril
formation by KE18-WT (125 lM) occurred at pH 7.0, and
gradually decreased in acidic pHs (Fig. 2b). Steady increase
of ﬁbril formation with increasing ionic strength was noted
from 0 to 1 M NaCl as shown in Fig. 2c. A mild decrease of
ﬁbril formation was noted in higher concentrations of NaCl
(2 and 4 M). Our results demonstrated that KE18-WT peptide
readily forms amyloid ﬁbrils under physiological conditions in
a time-dependent as well as pH- and ionic strength-dependent
manners.
3.3. Inhibition of the amyloid ﬁbril formation of KE18-WT by
N-methylation
We also attempted to further conﬁrm the amylodogenic nat-
ure of the synthetic peptides and inhibit the amyloid ﬁbril for-
mation with the N-methylation approach. By modifying thebackbone amino groups with N-methylation, formation of
the hydrogen bonds between peptide monomers can be pre-
vented and consequently, formation of beta-sheets and exten-
sion of the ﬁbrils are blocked (for review, see Ref. [20]). A
shorter synthetic peptide was used as a positive control in
our study (‘‘KE11-WT’’, Fig. 3a). Two related peptides,
namely MKE-A and MKE-B, were synthesized with tri-meth-
ylation of KE11-WT at three alternate residues (Fig. 3a) and
their respective capability for ﬁbril formation was examined.
Judging from the prominent ThT ﬂuorescence, KE11-WT pep-
tide (0.2 mM) as the positive control is highly amyloidogenic
and formed extensive ﬁbrils in vitro (Fig. 3b). The ﬁbril-form-
ing capacity of KE11-Wt is similar to that of KE18-WT as the
resultant ThT ﬂuorescence of KE11-WT mixed with KE18-
WT (0.4 mM total) was approximately two folds of that of
KE18-WT alone (0.2 mM) (Fig. 3c). In contrast, N-methylated
peptides MKE-A and MKE-B (0.2 mM) only had minimal
ﬂuorescence signals similar to that of buﬀer (Fig. 3b).
Fig. 3. Prevention of the amyloid ﬁbril formation by N-methylated
peptides. (a) The amino acid sequences of the putative amyloidogenic
motif within the KE18-WT peptide (‘‘KE11-WT’’) and two corre-
sponding peptides with N-methylation (‘‘MKE-A’’ and ‘‘MKE-B’’)
custom-synthesized for this study. The methyl groups replacing the
hydrogen atoms of the backbone amino groups in each amino acid are
denoted as encircled Ms. (b) ThT ﬂuorescence intensities as a function
of amyloid ﬁbril formation by these three related peptides were
determined by an fmax II plate reader with a ﬁlter set of 444 nm/
485 nm (ex/em) (n = 8, bars represent S.E.). KE11-WT peptide
(0.2 mM) as the positive control formed extensive ﬁbrils. N-methylated
peptides MKE-A and MKE-B only had minimal ﬂuorescence signals
similar to that of buﬀer. (c) KE18-WT was co-incubated with control
peptide (KE11-WT), buﬀer only or methylated peptides (MKE-A and
MKE-B) in equal molar ratios (0.2 mM each) and determined the ﬁbril
formation by ThT ﬂuorescence assays.
Fig. 2. Kinetics and eﬀects of ionic strength and pH on amyloid ﬁbril
formation of KE18-WT peptide. (a) Peptide samples (125 lM) were
incubated in 10 mM Tris–HCl, pH 7.0/150 mM NaCl at 37 C and the
ThT ﬂuorescence intensities at 485 nm were measured at 0, 1, 4, 8, 16,
24 and 48 h (n = 4, bars represent S.E.). Peptides (125 lM) were also
incubated at various pHs in 150 mM NaCl (b) or at various
concentrations of NaCl in 10 mM Tris–HCl, pH 7.0 (c). The formed
amyloid ﬁbrils in (b) and (c) were ﬁrst spun down by ultracentrifu-
gation before mixing with ThT solution. (n = 3, bars represent S.E.).
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eliminated its ﬁbril-forming potential and thus further con-
ﬁrmed the amyloidogenic nature of KE18-WT or related
KE11-WT in this previously unreported KE515-532 region.
Moreover, when these two N-methylated peptides were mixed
with KE18-WT and incubated for 24 h at 37 C, amyloid ﬁbril
formation was signiﬁcantly diminished by MKE-A or MKE-B
as compared to the combination of KE18-WT and KE11-WT
or KE18-WT only (Fig. 3c).3.4. Comparison of the amyloid ﬁbril formation between
KE18-WT and mutant peptides
As several corneal dystrophies have been linked to muta-
tions in this putatively amyloidogenic region, we further
examined the amyloid ﬁbril formation of synthetic peptides
containing mutations in this region (KE18-L518P, KE18-
L518R and KE18-L527R). The amyloidogenic ‘‘22R124C’’
peptide previously identiﬁed [3,16] that carries the R124C
mutation was also used for comparison. As shown in
Fig. 4, KE18-L527R displayed the highest ﬁbril formation
capability; formation was about 10 times higher than that
of KE18-WT peptide. Other related peptides such as
22R124C, KE18-L518P and KE18-L518R had less ﬁbril for-
mation than KE18-WT. Nonetheless, all of the synthetic pep-
tides with or without mutations in the region of a.a. 515 to
532 formed amyloid ﬁbrils in vitro. The respective amyloid
ﬁbril formation of these peptides was also conﬁrmed by
EM (data not shown).4. Discussion
More than 20 diﬀerent proteins or peptides have been shown
to cause amyloid diseases [21]. Although these disease-causingFig. 4. ThT ﬂuorescence spectra of synthetic peptides containing
dystrophy-related mutations. The propensity to form amyloid ﬁbrils
in vitro was determined for synthetic peptides (0.4 mM). Shown in
order from the highest emission intensity: KE18-L527R (tracing 1),
KE18-WT (tracing 2), 22R124C (tracing 3, Ref. [13]), KE18-L518P
(tracing 4), KE18-L518R (tracing 5) and ThT only (tracing 6).proteins do not share any sequence similarity, all of them form
amyloid ﬁbrils or non-amyloid amorphous aggregations with
human pathologies. Many other non-disease causing proteins
can also form amyloid ﬁbrils in vitro, therefore suggesting that
aggregation is a common characteristic of proteins. It is likely
that those non-disease causing proteins only form amyloid
ﬁbrils under certain conditions (albeit sometimes extreme
ones), whereas the disease-causing proteins form abnormal
ﬁbrils or aggregates due to protein unfoldings or abnormal
degradations under physiological conditions [21–23].
Despite relentless pursuits by various investigators, the amy-
loidogenic mechanism of KE-related corneal dystrophies re-
mains elusive. The available evidence directly related to the
amyloidgenesis of KE include the aberrant degradation and
turnover of mutant proteins from dystrophic corneas [10],
amyloid formation of recombinant KE proteins [17] and the
identiﬁcation of an amyloidogenic region in the N-terminus
including residue R124 [13,16]. Using synthetic peptides, we
have identiﬁed a previously unreported amyloidogenic locus
in KE from 515 to 532 a.a. located in the 4th Fas-1 domain
near the C-terminus. This domain contains a majority of ker-
atoepithelin mutations (such as mutations of L518 and L527
and R555) linked with various corneal dystrophies [4]. Syn-
thetic peptide KE18-WT forms ﬁbrils readily under physiolog-
ical conditions (pH 7.0, 150 mM NaCl) suggesting its potential
involvement in the amyloid ﬁbril formation. Further charac-
terization of the in vitro amyloidogenesis revealed a fast kinetic
rate of KE18-WT which reached the plateau within 48 h. The
amyloid ﬁbril formation can also be modulated by factors such
as pH and ionic strength. Not only did the WT synthetic pep-
tide form amyloid ﬁbrils as demonstrated by our studies with
ThT ﬂuorescence assay, Congo red birefringence meta-dichro-
matic staining, EM and CD spectroscopy, but modiﬁcation of
the backbone amino groups by N-methylation also completely
abolished its ﬁbril formation. By replacing the hydrogen atoms
of these amino groups with methyl groups, formation of the
hydrogen bonds between peptide monomers can be prevented.
Consequently, formation of b-sheets and extension of the
ﬁbrils are blocked. Using this N-methylation approach, several
groups have successfully inhibited ﬁbril formations of b-amy-
loid peptide [24–27] and islet amyloid polypeptide [28]
in vitro. Reduction of cytotoxicity induced by b-amyloid pep-
tide or already-formed ﬁbrils was also observed in PC12 cells
treated with methylated peptides [24]. The inhibition of amy-
loid ﬁbril formation by N-methylation as shown in Fig. 3b fur-
ther reconﬁrms the amyloidogenic nature of the synthetic
peptide. Abilities of using N-methylated peptides to inhibit
the ﬁbril formation of KE18-WT in vitro also suggest their po-
tential therapeutic application for KE-related corneal dystro-
phies. Overall, our amyloid ﬁbril formation setup is relatively
simple in contrast to the previously reported in vitro dialysis
setup for amyloid ﬁbril formation. Therefore, it could be of
potential use to study the aggregation mechanism of KE by
the synthetic peptide approach.
Our current study clearly indicates that the region contain-
ing residues 515 to 532 in KE is very amyloidogenic (or ﬁbrill-
ogenic). As total net charges on the b-sheet forming peptides
can be detrimental for ﬁbrillar aggregations as previously
shown [29] and the ionization of amino acids can be modulated
by pH, we also investigated the eﬀects of ionic strength and pH
on the amyloid ﬁbril formations of KE18-WT. The formation
of ﬁbrils increased steadily with the ionic strength and indeed
246 C. Yuan et al. / FEBS Letters 581 (2007) 241–247was aﬀected by pH. Based on our results, it is likely that the
ﬁbril formation of KE18-WT is aﬀected by electrostatic inter-
action, in addition to the hydrophobicity or b-sheet forming
propensity. The enhancement of ﬁbril formation with the ionic
strength seems to further support this notion. Furthermore,
our data suggest that mutations in this amyloidogenic region
do not necessarily lead to more extensive ﬁbril formation
(Fig. 4). Changing the residue 527 from a leucine to an arginine
(L527R mutation) which reduces the hydrophobicity and adds
a positive charge to the synthetic peptide resulted in signiﬁcant
increase of the amyloid ﬁbril formation as shown in Fig. 4.
However, the same leucine-to-arginine replacement at the
518 position (‘‘KE18-L518R’’) actually reduced ﬁbril-forming
capability and argues that additional factors may be involved
in the amyloid ﬁbril formation of KE18-WT. Previously, syn-
thetic peptides (‘‘bigh110–133’’) with dystrophy-related muta-
tions (R124C, R124H and R124S) were shown to have
higher ﬁbril-forming capabilities than the WT peptide [16].
However, they were shown later to be much less amyloidogenic
than a shorter yet much more potent peptide including a.a.
110–122 (‘‘bigh110–122’’) lacking the R124 residue [13]. It is
unclear whether individual mutation can transform the region
containing a.a. 110–133 to amyloidogenic one or exert their
eﬀects indirectly by modulating the 110–122 amyloidogenic
region. More data are deﬁnitely needed to determine whether
other dystrophy-related mutations distributed over various
regions on KE behave similarly.
Perhaps a more plausible, yet all-encompassing hypothesis is
that the dystrophy-related mutations distributed through KE
induce structural perturbation. Partially unfolded intermedi-
ates that initiate the nucleation and extension of the cross-b-
sheet polymers are critical for ﬁbril formation, as seen in
amyloid b precursor protein, lysozyme, insulin, transthyretin
and many others [30,31]. The resultant partial unfolding or
misfolding of KE mutants could expose the intrinsically amy-
loidogenic regions and promote their b-sheet polymerizations
that eventually leads to the amyloid ﬁbril or non-amyloid
amorphous aggregations. Although the structural data of
KE is currently lacking, model of the 4th Fas-1 domain in
KE has been proposed based on the crystal structure of
Drosophila fasciclin I domain [14]. The putative amyloido-
genic region (a.a. 515–532) is located within the predicted a1
and a2 helices connected by a loop. As residues L518 and
L527 are tightly packed by surrounding hydrophobic residues,
it is likely that mutations of these residues could disrupt the
packing and lead to structural changes or protein unfolding,
thereby initiating the abnormal aggregation process following
exposure of this amyloidogenic region. Mutations located
within these regions may or may not enhance their amyloido-
genic capabilities per se, but all can lead to the exposure of
amyloidogenic regions induced by protein unfolding and even-
tually the abnormal aggregations of KE. In addition, this re-
gion is part of a hydrophobic groove on the surface of the
4th Fas-1 domain and has been suggested to play signiﬁcant
roles in protein-protein interactions [14].
One interesting question that remains regarding the abnor-
mal aggregations of KE is why some mutations lead to amy-
loid ﬁbril formation (as in various lattice corneal
dystrophies) whereas other mutations cause non-amyloid
amorphous aggregation (as in granular dystrophies). For
example, R124C mutation leads to lattice dystrophy with char-
acteristic branching lattice lines of amyloid deposits, whereasR124S mutation causes granular dystrophy with amorphous
stromal aggregations. R124H mutation leads to Avellino dys-
trophy which displays both amyloid ﬁbril and non-amyloid
deposits in cornea. We have observed that KE18-WT peptide
forms both ﬁbrils and spheres in the morphological study by
EM. Similar spheres have been observed in transthyretin ﬁbrils
and were proposed to be one form of protoﬁbrils [32]. Alterna-
tively, they could represent the amorphous aggregates. The
mechanisms mediated by missense mutations to regulate the
formation of soluble oligomer, amyloid ﬁbrils or amorphous
aggregates by KE remain to be elucidated.
Concentrations of mutant KEs or accumulations of their de-
graded products may be another crucial factor in the patho-
genesis of KE-related corneal dystrophies. The onset of
corneal dystrophies ranges from as early as several months
of life to as late as the sixth of seven decades. During corneal
wound healing, the expression of KE is signiﬁcantly up-regu-
lated [33]. Accelerated progression of abnormal KE deposits
has been observed in dystrophic patients after LASIK surger-
ies [34]. The increased KE production in injured cornea may
therefore potentiate the abnormal aggregations. Based on the
diﬀerential degradation patterns of KE mutants versus WT
protein [10], it is likely that mutant proteins have altered pro-
tease susceptibilities that allow escape from normal protein
degradation to reach a critical concentration for amyloid ﬁbril
formation, or diﬀerential degradation to yield amyloidogenic
fragments leading to abnormal aggregations. Degraded pro-
tein fragments can form amyloid ﬁbrils as shown in amyloid
precursor protein and huntingtin [35,36]. Study of lactoferrin
also indicates that a highly amyloidogenic cleavage fragment
(containing NAGDVVAFV) initiates the ﬁbril formation
among peptides and then recruits the uncleaved full-length
protein for extensive aggregations [37]. It is yet to determine
whether proteolytic fragments containing the amyloidogenic
regions such as the one we identiﬁed here are present and
involved in the in vivo amyloid ﬁbril formation of KE mu-
tants. Furthermore, these amyloidogenic regions may also
form amyloid ﬁbrils in a homopolymeric (by themselves) or
heteropolymeric (collaborate with other amyloidogenic re-
gions) manner.
In summary, we have identiﬁed another amyloidogenic re-
gion on keratoepithelin. Our data disprove the notion that dys-
trophy-related mutations cause amyloid ﬁbril formation
directly by enhancing the amyloidogenic propensity. Rather,
the abnormal aggregations in KE-related corneal dystrophies
may be mediated by these putatively amyloidogenic regions
via alternative mechanisms such as mutation-induced protein
unfoldings and/or abnormal degradation. While the underly-
ing mechanism regarding the amyloid ﬁbril formation or
abnormal aggregations of mutant KEs in corneal dystrophies
awaits further study, further investigations into the roles of
these amyloidogenic regions in KE may help us to better
understand the pathogenesis of KE-related corneal dystro-
phies.
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